可能将 CXCL12 和 CXCR4 作为肿瘤标志物应用于乳腺癌患者的诊断。
Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer Patients.
机构信息
Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland
Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland.
出版信息
Anticancer Res. 2020 Jun;40(6):3221-3229. doi: 10.21873/anticanres.14303.
BACKGROUND/AIM: Chemokines are cytokines involved not only in inflammatory but also in inappropriate response of the immune system in breast cancer (BC) progression. We examined the diagnostic usefulness of CXCL12, CXCR4 and CA 15-3 in BC patients, based on ROC curve analysis.
MATERIALS AND METHODS
The study group consisted of 100 patients with BC; the control group consisted of 35 women with benign breast disease and 35 healthy patients. The median concentration of chemokines was measured by ELISA and that of CA 15-3 by chemiluminescent microparticle immunoassay.
RESULTS
The concentrations of CXCL12 and CXCR4 in the BC group were significantly higher than those in the control groups. The AUC value of CXCL12 (0.7502) was the highest of all the chemokines measured in the BC patients.
CONCLUSION
There may be a link between CXCL12, CXCR4 and BC that can assist in the diagnosis, markedly when combined with CA 15-3.
背景/目的：趋化因子不仅参与炎症反应，还参与乳腺癌（BC）进展中免疫系统的异常反应。我们通过 ROC 曲线分析，检查了 CXCL12、CXCR4 和 CA 15-3 在 BC 患者中的诊断价值。
材料和方法
研究组包括 100 例 BC 患者，对照组包括 35 例良性乳腺疾病患者和 35 例健康患者。通过 ELISA 测量趋化因子的中位数浓度，通过化学发光微粒子免疫测定法测量 CA 15-3 的浓度。
结果
BC 组的 CXCL12 和 CXCR4 浓度明显高于对照组。在 BC 患者中测量的所有趋化因子中，CXCL12 的 AUC 值（0.7502）最高。
结论
CXCL12、CXCR4 与 BC 之间可能存在联系，有助于诊断，尤其是与 CA 15-3 联合使用时。
Zotero 插件